SCHEMBL5362995

SCHEMBL5362995

CC(C)(C)[Si](C)(C)Oc1ccc(C2CCC(NS(=O)(=O)c3ccc(Cl)cc3)CC2)c(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.41
HTR7 P34969 3/20 0.41
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
DRD2 P14416 2/20 0.38
ADRA1D P25100 2/20 0.38
ADRA1A P35348 2/20 0.38
ADRA1B P35368 2/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
KIT P10721 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5362991 1.00 HTR1A (0.41) HTR1AHTR7POLBMAPK1SMN1; SMN2
SCHEMBL5360944 0.91 POLB (0.40) POLBSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL5363070 0.91 ALDH1A1 (0.45) POLBSMN1; SMN2TP53DRD2LMNA
SCHEMBL5359455 0.91 ALDH1A1 (0.45) POLBSMN1; SMN2TP53DRD2LMNA
SCHEMBL5446985 0.91 POLB (0.42) POLBMAPK1SMN1; SMN2PDE4APDE4B
SCHEMBL5359450 0.91 ALDH1A1 (0.45) POLBSMN1; SMN2TP53DRD2LMNA
SCHEMBL5360942 0.91 POLB (0.40) POLBSMN1; SMN2PDE4APDE4BPDE4C
SCHEMBL5446988 0.91 POLB (0.42) POLBMAPK1SMN1; SMN2PDE4APDE4B
SCHEMBL5361293 0.91 KMT2A (0.44) HTR7MAPK1SMN1; SMN2TP53PKM
SCHEMBL5361288 0.91 KMT2A (0.44) HTR7MAPK1SMN1; SMN2TP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7282592-B2 Resorcinol derivatives WARNER-LAMBERT COMPANY (US) 2007-10-16 US disclosed
US-20070122367-A1 RESORCINOL DERIVATIVES PFIZER INC. (US) 2007-05-31 US disclosed
US-7173052-B2 Resorcinol derivatives PFIZER INC. (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070122367-A1 RESORCINOL DERIVATIVES LRAT, NQO1, ALDH1A2 HTR1A 3210/4885HTR7 4318/4885POLB 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.